Compare Nike Inc (NKE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Nike (NKE) trades at $41.32, down 0.91% on the day, reflecting near-term pressure amid a bearish technical signal. The stock shows strong profitability with a 42.91% gross margin and 22.14% ROE, but revenue declined to $46.31B in 2025. Recent quarters have consistently beaten EPS estimates, with Q1 2026 EPS of $0.72 significantly exceeding expectations. Analysts maintain a consensus Buy rating with a $50.45 price target, indicating potential upside from current levels.

The outlook balances solid brand strength and earnings beats against revenue headwinds and competitive pressures. Investment opportunity lies in valuation discount to analyst targets and operational discipline, but risks include sluggish demand in key markets like China and margin compression from promotional activity.

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.